Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-12-02 Share Issue/Capital Cha…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
Share Issue/Capital Change Classification · 95% confidence The document is a monthly return report detailing movements in authorised/registered share capital and issued shares for the month ended 30 November 2022. It includes confirmations related to share issuance and compliance with listing rules. The content focuses on share capital and share issuance movements without financial statements or earnings data. It is a regulatory compliance filing related to share capital movements rather than a financial report or announcement of a report. The document is about share capital and share issuance but does not announce new share issues or capital changes explicitly as a separate event; rather, it reports monthly movements and confirmations. Therefore, the best fitting category is 'Share Issue/Capital Change (SHA)' as it relates to share capital and share issuance movements under listing rules.
2022-12-02 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-11-29 English
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO PROPERTY SERVICES
Regulatory Filings Classification · 95% confidence The document is an announcement related to continuing connected transactions concerning property services between the company and its connected persons. It discusses framework agreements, annual caps, and the need for shareholder approval at an Extraordinary General Meeting (EGM). The content is focused on contractual arrangements and regulatory compliance under listing rules, rather than financial results, management changes, or other report types. It is a regulatory announcement about connected transactions and shareholder meeting arrangements, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-23 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-11-10 English
VOLUNTARY ANNOUNCEMENT-CENTER FOR DRUG EVALUATION (CDE) OF THE NMPA PROPOSED TO GRANT TELITACICEPT BREAKTHROUGH THERAPY DESIGNATION FOR THE TREATMENT OF GENERALISED MYASTHENIA GRAVIS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the proposal by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to grant breakthrough therapy designation for a drug (telitacicept) for the treatment of myasthenia gravis. The content focuses on regulatory and clinical trial updates about the drug development status and does not contain financial data, earnings, management changes, or detailed report information. The document is relatively short (4239 characters) and serves as an announcement rather than a detailed report or filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about drug development status, which aligns best with Regulatory Filings (RNS) as a general regulatory announcement category. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-11-10 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 9 NOVEMBER 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from an Extraordinary General Meeting (EGM) held on 9 November 2022. It details the voting outcome on a specific resolution related to a proposed disposal and mandate to directors. The text references the EGM Notice and Circular but does not contain the full text of those documents or detailed financial data. The document is short (3554 characters) and serves to officially communicate the voting results rather than the meeting materials or the resolution details themselves. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.